Rise in incidence of endometriosis is responsible for the notable growth of the endometriosis treatment market. As there are a handful of relieving procedures available, there is a scope for extensive research in this regard. Several clinical trials are being conducted with the objective of having a robust line of treatment in place.
WILMINGTON, Del. , July 26, 2024 /PRNewswire/ -- The market for endometriosis treatment is projected to attain a value of US$ 3.1 billion by 2034.
According to Transparency Market Research, the landscape was valued at US$ 1.4 billion in 2023 . From 2024 to 2034, the market is anticipated to advance at a CAGR of 7.
5%. Peritoneal and ovarian endometriosis treatments are well established, with laparoscopic cystectomy for ovarian endometriomas outperforming drainage and electrocoagulation. Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain.
Newer medications, such as GnRH antagonists like Elagolix and Letrozole, have showed promise, especially in terms of pain relief and fertility outcomes. Despite the range of treatment choices, the market faces obstacles in providing effective long-term solutions that do not jeopardize fertility. Drugs such as Elagolix, which was licensed by the FDA in 2018, have considerable potential but require additional investigation, particularly in terms of its usage in pre-treatment prior to in vitro fertilization.